BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Wednesday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Stock Up 12.8 %

BIOL opened at $0.01 on Wednesday. BIOLASE has a twelve month low of $0.02 and a twelve month high of $1.94. The company has a 50-day moving average price of $0.01 and a 200 day moving average price of $0.02. The company has a market cap of $293,981.60, a PE ratio of 0.00 and a beta of 0.67.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.